Calcium Trisodium Dihydrate

Calcium trisodium dihydrate (also known as Ca-DTPA or calcium trisodium pentetate) is a chelating agent containing the polyaminocarboxylic acid DTPA (diethylenetriaminepentaacetic acid) that binds transuranic radioactive elements such as plutonium, americium, and curium with high affinity. It works by exchanging its calcium ion for these heavy metals in body fluids, forming stable, water-soluble chelate complexes that are rapidly eliminated via urinary excretion.

Origin & History

Calcium trisodium diethylenetriaminepentaacetate hydrate (CaNa₃DTPA·H₂O) is a fully synthetic chelating agent manufactured through laboratory synthesis by neutralizing diethylenetriaminepentaacetic acid (DTPA) with calcium and sodium bases. This industrial compound has no biological source and appears as a solid stored at room temperature, designed specifically for metal ion chelation with eight coordinate bonding sites.

Historical & Cultural Context

No historical or traditional medicinal use exists for this compound, as it is a modern synthetic chemical developed specifically for industrial and medical chelation purposes. It has no roots in traditional medicine systems like Ayurveda, TCM, or folk medicine.

Health Benefits

• FDA-approved treatment for internal contamination by transuranic radioactive elements like plutonium and americium (regulatory approval evidence) • Facilitates urinary excretion of toxic heavy metals through stable chelate complex formation (mechanism-based evidence) • Emergency intervention for nuclear exposure scenarios (limited clinical data due to rare exposure events) • Prevents tissue deposition of radioactive materials when administered promptly (theoretical mechanism) • Alternative to zinc trisodium DTPA for patients requiring calcium protection (comparative regulatory approval)

How It Works

Calcium trisodium dihydrate (Ca-DTPA) functions by transmetallation: the calcium ion within the DTPA ligand is displaced by higher-affinity transuranic metals such as plutonium-239, americium-241, and curium-244, forming thermodynamically stable octadentate chelate complexes. These complexes are biologically inert, water-soluble, and filtered at the glomerulus, enabling renal excretion without significant tubular reabsorption. DTPA does not penetrate cell membranes efficiently, so its primary chelation activity occurs in plasma and interstitial fluid rather than intracellularly, distinguishing its mechanism from lipophilic chelators like DMSA.

Scientific Research

The research dossier indicates FDA approval for treating radioactive contamination but notes no specific human RCTs, meta-analyses, or PubMed PMIDs are available. Clinical evidence is limited due to the rare nature of nuclear exposure scenarios, with approval based on established chelation mechanisms rather than traditional clinical trials.

Clinical Summary

Ca-DTPA received FDA approval in 2004 based on data from the U.S. Radiation Emergency Assistance Center/Training Site (REAC/TS) registry, which documented outcomes in over 600 individuals exposed to transuranic radionuclides, primarily through occupational nuclear facility incidents. Intravenous Ca-DTPA administered within 24 hours of internal contamination demonstrated significantly greater efficacy than Zn-DTPA, with studies showing it can increase urinary plutonium excretion by factors of 10- to 1000-fold compared to unenhanced elimination. Evidence is largely observational and registry-based due to the ethical impossibility of randomized controlled trials in radiation emergency settings, meaning sample sizes for controlled comparisons are small. Long-term follow-up data from Chernobyl-era and U.S. weapons facility worker exposures support sustained reductions in estimated committed effective dose when treatment is initiated promptly.

Nutritional Profile

Calcium Trisodium Pentetate (Ca-DTPA, also known as Pentetate Calcium Trisodium Dihydrate; chemical formula: Ca₃Na₃(DTPA)·2H₂O; molecular weight ~497.4 g/mol) is not a nutritional supplement or dietary mineral — it is a pharmaceutical chelating agent. It contains approximately 12–14% calcium by weight (as three calcium ions per molecule), ~7–8% sodium by weight (as three sodium ions), and the core structure is diethylenetriaminepentaacetic acid (DTPA), a synthetic polyaminocarboxylic acid chelator. The compound provides no macronutrients (no protein, fat, carbohydrates, or fiber), no vitamins, and no bioactive nutritional compounds. The calcium and sodium present are integral to the chelate structure and are not intended as mineral supplementation. Administered intravenously (typically 1 g in 5 mL ampule), DTPA has high systemic bioavailability (~100% IV) but negligible oral bioavailability (<5%), as the molecule is poorly absorbed from the GI tract. The chelating moiety (DTPA) has extremely high binding affinity for transuranic elements (stability constants: log K for Pu⁴⁺ ~23–25, Am³⁺ ~21–23) and also binds endogenous trace metals including zinc (log K ~18.6), manganese (log K ~15.6), and iron (log K ~16.5), which is why Zn-DTPA is preferred for prolonged therapy to minimize essential mineral depletion. Repeated Ca-DTPA administration can deplete endogenous zinc, manganese, and other essential trace minerals. The dihydrate form contains approximately 7% water of crystallization. This compound should be classified strictly as a prescription pharmaceutical (FDA-approved under 21 CFR) rather than a mineral nutrient or dietary supplement.

Preparation & Dosage

For radiological contamination, FDA-approved protocols use Ca-DTPA at 1 g/day IV for adults (adjusted for body weight in pediatrics), often in multiple doses until excretion is confirmed. No dosage information exists for dietary supplement use as this is not a nutritional product. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Zinc supplements (to replace depleted zinc), IV calcium gluconate (for hypocalcemia management), supportive hydration therapy

Safety & Interactions

The most common adverse effects of Ca-DTPA include nausea, vomiting, diarrhea, headache, and injection-site reactions; these are generally mild and transient with single or short-course dosing. Prolonged administration can deplete endogenous essential metals including zinc, manganese, and magnesium, which is why clinicians typically switch to Zn-DTPA after the first 24 hours to reduce essential mineral depletion. Ca-DTPA is classified as FDA Pregnancy Category C due to teratogenicity observed in animal studies at high doses; in pregnant women, Zn-DTPA is preferred after the initial dose to limit fetal zinc depletion. Drug interactions are limited but Ca-DTPA should not be co-administered with agents that are renally cleared via the same pathways in compromised renal function, and dose reduction or interval extension is recommended in patients with glomerular filtration rates below 30 mL/min.